{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:40:14Z","timestamp":1794375614557,"version":"4.9.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41591-026-04642-w","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:03:16Z","timestamp":1789117396000},"page":"3812-3822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-4277","authenticated-orcid":false,"given":"Omar","family":"Nadeem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9198-8338","authenticated-orcid":false,"given":"David M.","family":"Cordas dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Magidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Matous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Medvedova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Redd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4948-5507","authenticated-orcid":false,"given":"Shonali","family":"Midha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-4413","authenticated-orcid":false,"given":"Adam S.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Arters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Davie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Toenges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayda","family":"Bidikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subear","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Alberge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungjae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Pantano-Rubino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Addonizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siham","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlee","family":"Sturtevant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Marto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Malfona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7430-1399","authenticated-orcid":false,"given":"Kevin","family":"Panaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-4669","authenticated-orcid":false,"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5218-5666","authenticated-orcid":false,"given":"Lorenzo","family":"Trippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"4642_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495\u2013505 https:\/\/doi.org\/10.1056\/NEJMoa2203478 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4642_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01259-z","volume":"15","author":"CR Tan","year":"2025","unstructured":"Tan, C. R. et al. Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): an International Myeloma Working Group study. Blood Cancer J. 15, 53 https:\/\/doi.org\/10.1038\/s41408-025-01259-z (2025).","journal-title":"Blood Cancer J."},{"key":"4642_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01003-z","volume":"14","author":"M Mohan","year":"2024","unstructured":"Mohan, M. et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 14, 35 https:\/\/doi.org\/10.1038\/s41408-024-01003-z (2024).","journal-title":"Blood Cancer J."},{"key":"4642_CR4","doi-asserted-by":"publisher","unstructured":"Dima, D. et al. Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience. Transplant. Cell Ther. 30, 308.e1\u2013308.e13 https:\/\/doi.org\/10.1016\/j.jtct.2023.12.016 (2024).","DOI":"10.1016\/j.jtct.2023.12.016"},{"key":"4642_CR5","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1056\/NEJMoa2514663","volume":"394","author":"LJ Costa","year":"2026","unstructured":"Costa, L. J. et al. Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 394, 739\u2013752 https:\/\/doi.org\/10.1056\/NEJMoa2514663 (2026).","journal-title":"N. Engl. J. Med."},{"key":"4642_CR6","doi-asserted-by":"publisher","unstructured":"Mina, R. et al. MajesTEC-9: a phase 3 randomized study of teclistamab monotherapy vs investigator\u2019s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd\/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM). J. Clin. Oncol. 44, 7507 https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.7507 (2026).","DOI":"10.1200\/JCO.2026.44.16_suppl.7507"},{"key":"4642_CR7","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/s41588-025-02196-0","volume":"57","author":"J-B Alberge","year":"2025","unstructured":"Alberge, J.-B. et al. Genomic landscape of multiple myeloma and its precursor conditions. Nat. Genet. 57, 1493\u20131503 (2025).","journal-title":"Nat. Genet."},{"key":"4642_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1200\/JCO-25-00289","volume":"44","author":"A Aktas Samur","year":"2026","unstructured":"Aktas Samur, A. et al. Genomically smoldering multiple myeloma is not a distinct entity but a collection of monoclonal gammopathy of undetermined significance or multiple myeloma. J. Clin. Oncol. 44, 321\u2013334 (2026).","journal-title":"J. Clin. Oncol."},{"key":"4642_CR9","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1038\/s41588-025-02292-1","volume":"57","author":"F Maura","year":"2025","unstructured":"Maura, F. et al. Temporal genomic dynamics shape clinical trajectory in multiple myeloma. Nat. Genet. 57, 2203\u20132214 (2025).","journal-title":"Nat. Genet."},{"key":"4642_CR10","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","volume":"110","author":"E P\u00e9rez-Persona","year":"2007","unstructured":"P\u00e9rez-Persona, E. et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110, 2586\u20132592 https:\/\/doi.org\/10.1182\/blood-2007-05-088443 (2007).","journal-title":"Blood"},{"key":"4642_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"MV Mateos","year":"2020","unstructured":"Mateos, M. V. et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 10, 102 https:\/\/doi.org\/10.1038\/s41408-020-00366-3 (2020).","journal-title":"Blood Cancer J."},{"key":"4642_CR12","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","volume":"10","author":"A Cowan","year":"2023","unstructured":"Cowan, A. et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematol. 10, e203\u2013e212 (2023).","journal-title":"Lancet Haematol."},{"key":"4642_CR13","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","volume":"111","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri, A. et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111, 785\u2013789 https:\/\/doi.org\/10.1182\/blood-2007-08-108357 (2008).","journal-title":"Blood"},{"key":"4642_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman, A. et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 8, 59 https:\/\/doi.org\/10.1038\/s41408-018-0077-4 (2018).","journal-title":"Blood Cancer J."},{"key":"4642_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.65","volume":"6","author":"P Ravi","year":"2016","unstructured":"Ravi, P. et al. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J. 6, e454 (2016).","journal-title":"Blood Cancer J."},{"key":"4642_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij, O. et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat. Cancer 1, 493\u2013506 https:\/\/doi.org\/10.1038\/s43018-020-0053-3 (2020).","journal-title":"Nat. Cancer"},{"key":"4642_CR17","doi-asserted-by":"publisher","unstructured":"Schinke, C. et al. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Adv. 6, 5873\u20135883 https:\/\/doi.org\/10.1182\/bloodadvances.2022007217 (2022).","DOI":"10.1182\/bloodadvances.2022007217"},{"key":"4642_CR18","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.ccell.2022.10.017","volume":"40","author":"R Sklavenitis-Pistofidis","year":"2022","unstructured":"Sklavenitis-Pistofidis, R. et al. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell 40, 1358\u20131373 https:\/\/doi.org\/10.1016\/j.ccell.2022.10.017 (2022).","journal-title":"Cancer Cell"},{"key":"4642_CR19","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41568-024-00755-x","volume":"24","author":"DM Cordas dos Santos","year":"2024","unstructured":"Cordas dos Santos, D. M., Toenges, R., Bertamini, L., Alberge, J.-B. & Ghobrial, I. M. New horizons in our understanding of precursor multiple myeloma and early interception. Nat. Rev. Cancer 24, 867\u2013886 https:\/\/doi.org\/10.1038\/s41568-024-00755-x (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"4642_CR20","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","volume":"392","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos, M. A. et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. N. Engl. J. Med. 392, 1777\u20131788 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4642_CR21","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos, M. V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438\u2013447 https:\/\/doi.org\/10.1056\/NEJMoa1300439 (2013).","journal-title":"N. Engl. J. Med."},{"key":"4642_CR22","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J. Clin. Oncol. 38, 1126\u20131137 https:\/\/doi.org\/10.1200\/JCO.19.01740 (2020).","journal-title":"J. Clin. Oncol."},{"key":"4642_CR23","doi-asserted-by":"publisher","unstructured":"Nadeem, O. Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial. Nat. Commun. 16, 358 https:\/\/doi.org\/10.1038\/s41467-024-55308-5 (2025).","DOI":"10.1038\/s41467-024-55308-5"},{"key":"4642_CR24","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1200\/JCO.23.02771","volume":"42","author":"MV Mateos","year":"2024","unstructured":"Mateos, M. V. et al. Curative strategy for high-risk smoldering myeloma: carfilzomib, lenalidomide, and dexamethasone (KRd) followed by transplant, KRd consolidation, and Rd maintenance. J. Clin. Oncol. 42, 3247\u20133256 https:\/\/doi.org\/10.1200\/JCO.23.02771 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4642_CR25","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1182\/blood.2024026212","volume":"144","author":"H Lee","year":"2024","unstructured":"Lee, H. et al. Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma. Blood 144, 2637\u20132651 https:\/\/doi.org\/10.1182\/blood.2024026212 (2024).","journal-title":"Blood"},{"key":"4642_CR26","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","volume":"7","author":"S Girgis","year":"2023","unstructured":"Girgis, S. et al. Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma. Blood Adv. 7, 644\u2013648 (2023).","journal-title":"Blood Adv."},{"key":"4642_CR27","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1038\/s41375-025-02757-6","volume":"39","author":"S Neubert","year":"2025","unstructured":"Neubert, S. et al. Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma. Leukemia 39, 2563\u20132567 (2025).","journal-title":"Leukemia"},{"key":"4642_CR28","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1038\/s43018-025-01006-0","volume":"6","author":"ED Lightbody","year":"2025","unstructured":"Lightbody, E. D. et al. SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors. Nat. Cancer 6, 1595\u20131611 https:\/\/doi.org\/10.1038\/s43018-025-01006-0 (2025).","journal-title":"Nat. Cancer"},{"key":"4642_CR29","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1001\/jamaoncol.2021.3971","volume":"7","author":"D Kazandjian","year":"2021","unstructured":"Kazandjian, D. et al. Carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance for prevention of symptomatic multiple myeloma in patients with high-risk smoldering myeloma: a phase 2 nonrandomized controlled trial. JAMA Oncol. 7, 1678\u20131685 https:\/\/doi.org\/10.1001\/jamaoncol.2021.3971 (2021).","journal-title":"JAMA Oncol."},{"key":"4642_CR30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-202653","volume":"144","author":"O Nadeem","year":"2024","unstructured":"Nadeem, O. et al. Phase II trial of daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering multiple myeloma. Blood 144, 3360 https:\/\/doi.org\/10.1182\/blood-2024-202653 (2024).","journal-title":"Blood"},{"key":"4642_CR31","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood-2022-168930","volume":"140","author":"SK Kumar","year":"2022","unstructured":"Kumar, S. K. et al. Fixed duration therapy with daratumumab, carfilzomib, lenalidomide and dexamethasone for high risk smoldering multiple myeloma-results of the ascent trial. Blood 140, 1830\u20131832 https:\/\/doi.org\/10.1182\/blood-2022-168930 (2022).","journal-title":"Blood"},{"key":"4642_CR32","doi-asserted-by":"publisher","unstructured":"Nadeem, O. et al. Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial. Nat. Med. 32, 2420\u20132429 https:\/\/doi.org\/10.1038\/s41591-026-04365-y (2026).","DOI":"10.1038\/s41591-026-04365-y"},{"key":"4642_CR33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-367","volume":"146","author":"S Manier","year":"2025","unstructured":"Manier, S. et al. A phase 2 study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: the IFM2021-01 teclille trial, cohort A. Blood 146, 367 (2025).","journal-title":"Blood"},{"key":"4642_CR34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206003","volume":"144","author":"MS Raab","year":"2024","unstructured":"Raab, M. S. et al. Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) trial. Blood 144, 493 (2024).","journal-title":"Blood"},{"key":"4642_CR35","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee, H. et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat. Med. 29, 2295\u20132306 https:\/\/doi.org\/10.1038\/s41591-023-02491-5 (2023).","journal-title":"Nat. Med."},{"key":"4642_CR36","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1182\/blood.2023023557","volume":"144","author":"RS Firestone","year":"2024","unstructured":"Firestone, R. S. et al. Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma. Blood 144, 402\u2013407 https:\/\/doi.org\/10.1182\/blood.2023023557 (2024).","journal-title":"Blood"},{"key":"4642_CR37","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich, M. J. et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell 41, 711\u2013725 (2023).","journal-title":"Cancer Cell"},{"key":"4642_CR38","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1016\/j.ymthe.2025.03.048","volume":"33","author":"T Tix","year":"2025","unstructured":"Tix, T. et al. Non-relapse mortality with bispecific antibodies: a systematic review and meta-analysis in lymphoma and multiple myeloma. Mol. Ther. 33, 3163\u20133176 https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.048 (2025).","journal-title":"Mol. Ther."},{"key":"4642_CR39","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie, B. G. et al. International uniform response criteria for multiple myeloma. Leukemia 20, 1467\u20131473 (2006).","journal-title":"Leukemia"},{"key":"4642_CR40","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"4642_CR41","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","volume":"158","author":"E Sanchez","year":"2012","unstructured":"Sanchez, E. et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br. J. Haematol. 158, 727\u2013738 (2012).","journal-title":"Br. J. Haematol."},{"key":"4642_CR42","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3324\/haematol.2016.150896","volume":"102","author":"M Ghermezi","year":"2016","unstructured":"Ghermezi, M. et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica 102, 785\u2013795 (2016).","journal-title":"Haematologica"},{"key":"4642_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00505-4","volume":"11","author":"A Visram","year":"2021","unstructured":"Visram, A. et al. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J. 11, 120 (2021).","journal-title":"Blood Cancer J."},{"key":"4642_CR44","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1158\/2159-8290.CD-22-0482","volume":"13","author":"K Ankit","year":"2023","unstructured":"Ankit, K. et al. MinimuMM-seq: genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology. Cancer Discov. 13, 348\u2013363 (2023).","journal-title":"Cancer Discov."},{"key":"4642_CR45","doi-asserted-by":"publisher","unstructured":"Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.1303.3997 (2013).","DOI":"10.48550\/arXiv.1303.3997"},{"key":"4642_CR46","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591\u2013594 (2018).","journal-title":"Nat. Methods"},{"key":"4642_CR47","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413\u2013421 (2012).","journal-title":"Nat. Biotechnol."},{"key":"4642_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg2538","volume":"372","author":"LM Morton","year":"2021","unstructured":"Morton, L. M. et al. Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident. Science 372, eabg2538 (2021).","journal-title":"Science"},{"key":"4642_CR49","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/bjh.15003","volume":"180","author":"B Foulk","year":"2018","unstructured":"Foulk, B. et al. Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders. Br. J. Haematol. 180, 71\u201381 (2018).","journal-title":"Br. J. Haematol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04642-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04642-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04642-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:12:26Z","timestamp":1794327146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04642-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4642"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04642-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.N. receives research funding from BMS and JNJ, and serves on advisory boards for BMS, JNJ, Sanofi, GPCR Therapeutics, Kite Pharma and AstraZeneca. D.M.C.d.S. receives research funding from Regeneron. E.M. receives research funding from JNJ, AbbVie and AstraZeneca, and is a consultant at Prothena. E.O. serves as a consultant for Exact Sciences, Natera, GRAIL and Sanofi, and receives research funding from Regeneron. Y.L. has participated on an advisory board for Opna Bio and consulted for Sanofi. A.S.S. has consulted for Novartis and Janssen. P.G.R. serves as a consultant for Celgene\/BMS, GSK, Karyopharm, Oncopeptides, Regeneron and Sanofi, and recieves research grants from Oncopeptides and Karyopharm. J.R. has research funding from Kite Pharma\/Gilead and Novartis, and serves on advisory boards for Astraveus, CGT Global, Smart Immune, Stratus Therapeutics, Tolerance Bio and Visterra. I.M.G. has consulted for AbbVie, Adaptive Biotechnologies, Amgen, Aptitude Health, Arcellx, AstraZeneca, BioSkryb Genomics, Bristol Myers Squibb, Civala, Clinical Care Options, Clinical Education Alliance, ENGAGE, Feromics, Genentech, GlaxoSmithKline, Janssen, Kite Pharma, Menarini Silicon Biosystems, ONK Therapeutics, Pfizer, Regeneron, Sanofi, Silicon Biosystems, Takeda, TG Therapeutics and Window Therapeutics; has received honoraria from Amgen, Curio Science, Janssen, MD Education, MJH Life Sciences, Physicians\u2019 Education Resource, Regeneron, Standard BioTools, Takeda, Thermo Fisher Scientific\/Binding Site, Veeva and Vor Biopharma; and is also a founder and executive board member of, and holds private equity in, Predicta Biosciences. Her spouse is the chief medical officer of, and holds private equity in, Disc Medicine. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}